Publications by authors named "Ileana Sparagna"

Article Synopsis
  • * Researchers compared hormone levels among three groups: male patients with ALK-positive ANSCLC (cohort A), female patients with ALK-positive ANSCLC (cohort B), and male patients with ALK-negative ANSCLC (cohort C).
  • * Results indicated that male patients in cohort A had significantly lower testosterone and higher follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels compared to cohort C, suggesting that androgen deficiency symptoms should
View Article and Find Full Text PDF
Article Synopsis
  • In patients with extensive-stage small cell lung cancer (ES-SCLC) receiving maintenance immunotherapy (IT), higher levels of the adipokine leptin and a favorable leptin-to-visceral fat ratio were linked to improved progression-free survival (PFS).
  • A study using blood samples and CT scans found that clusters of patients with high leptin and low pro-inflammatory markers had better outcomes, with significantly longer PFS and overall survival (OS) compared to others.
  • The findings suggest that adipokines may influence the effectiveness of immunotherapy in cancer treatment, indicating a need for further research on metabolic immune dysfunctions in a larger patient cohort.
View Article and Find Full Text PDF
Article Synopsis
  • The role of Aurora kinases (AURKs) in cell cycle regulation is significant, as their hyperexpression contributes to cancer progression and drug resistance in both NSCLC and SCLC.
  • This review aims to examine the evidence surrounding AURK inhibitors in lung cancer, encompassing studies from preclinical phases to ongoing clinical trials.
View Article and Find Full Text PDF

Non-small cell lung cancer (NSCLC) represents the perfect paradigm of 'precision medicine' due to its complex intratumoral heterogeneity. It is truly characterized by a range of molecular alterations that can deeply influence the natural history of this disease. Several molecular alterations have been found over time, paving the road to biomarker-driven therapy and radically changing the prognosis of 'oncogene addicted' NSCLC patients.

View Article and Find Full Text PDF